Liraglutide Anti-Diabetics don Kula da Sugar Jini CAS NO.204656-20-2
Cikakken Bayani
| CAS | 204656-20-2 | Tsarin kwayoyin halitta | C172H265N43O51 |
| Nauyin Kwayoyin Halitta | 3751.20 | Bayyanar | Fari |
| Yanayin Ajiya | Juriya mai haske, digiri 2-8 | Kunshin | Aluminum foil jakar / vial |
| Tsafta | ≥98% | Sufuri | Sarkar sanyi da isar da ajiya mai sanyi |
Abubuwan da ke cikin Liraglutide
Abunda yake aiki:
Liraglutide (analog na ɗan adam glucagon-kamar peptide-1 (GLP-1) wanda yisti ke samarwa ta hanyar fasahar sake haɗuwa da kwayoyin halitta).
Sunan Sinadari:
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl))))-GLP-1[7-37]
Sauran Sinadaran:
Disodium Hydrogen Phosphate Dihydrate, Propylene Glycol, Hydrochloric Acid da/ko Sodium Hydroxide (a matsayin pH Adjusters Only), Phenol, da Ruwa don allura.
Aikace-aikace
Nau'in ciwon sukari na 2
Liraglutide yana inganta sarrafa glucose na jini.Yana rage hyperglycemia da ke da alaƙa da abinci (na awanni 24 bayan gudanarwa) ta hanyar haɓaka haɓakar insulin (kawai) lokacin da ake buƙata ta hanyar haɓaka matakan glucose, jinkirta zubar da ciki, da kuma kawar da ɓoyewar glucagon prandial.
Ya dace da marasa lafiya waɗanda har yanzu ba a sarrafa sukarin jininsu ba bayan matsakaicin adadin jurewar metformin ko sulfonylureas kaɗai.Ana amfani dashi a hade tare da metformin ko sulfonylureas.
Yana aiki ne ta hanyar dogaro da glucose, ma'ana zai haifar da sakin insulin kawai lokacin da matakan glucose na jini ya fi na al'ada, yana hana "cirewa".A sakamakon haka, yana nuna haɗarin haɗarin hypoglycemia.
Yana da yuwuwar hana apoptosis da haɓaka haɓakar ƙwayoyin beta (wanda aka gani a cikin binciken dabba).
Yana rage sha'awa kuma yana hana nauyin jiki, kamar yadda aka nuna a cikin binciken kai-da-kai da glimepiride.
Ayyukan Pharmacological
Liraglutide shine analog na GLP-1 tare da homology na 97% ga ɗan adam GLP-1, wanda zai iya ɗaure da kunna mai karɓar GLP-1.Mai karɓa na GLP-1 shine manufa na GLP-1 na asali, wani hormone incretin na endogenous wanda ke inganta ƙwayar insulin mai dogara da glucose daga ƙwayoyin β pancreatic.Ba kamar GLP-1 na asali ba, bayanan pharmacokinetic da pharmacodynamic na liraglutide a cikin mutane sun dace da tsarin yin allurai sau ɗaya a rana.Bayan allurar subcutaneous, tsarin aikinta na tsawon lokaci ya haɗa da: haɗin kai wanda ke jinkirta sha;dauri ga albumin;Mafi girman kwanciyar hankali na enzyme kuma don haka tsawon rabin rayuwar plasma.
Ayyukan liraglutide yana shiga tsakani ta takamaiman hulɗarsa tare da mai karɓar GLP-1, wanda ke haifar da haɓaka adenosine monophosphate na cyclic (cAMP).Liraglutide yana motsa fitar da insulin ta hanyar dogaro da glucose, yayin da yake rage yawan glucagon ta hanyar dogaro da glucose.
Sabili da haka, lokacin da glucose na jini ya tashi, ƙwayar insulin yana motsawa, yayin da ƙwayar glucagon ke hana.Sabanin haka, liraglutide yana rage fitowar insulin a lokacin hypoglycemia ba tare da tasirin glucagon ba.Tsarin hypoglycemic na liraglutide shima ya haɗa da ɗan tsawaita lokacin zubar da ciki.Liraglutide yana rage nauyin jiki da kitsen jiki ta hanyar rage yunwa da kuzari.
